Childhood Cancer Clinical Trials Act
December 17, 2024
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
Where This Stands
Currently IN_COMMITTEE. The next step in the legislative lifecycle is Floor Vote.
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →The Frame
If passed, this bill would ensure that families of children with rare diseases do not face higher out-of-pocket costs when seeking specialized care at out-of-network facilities for approved clinical trials, effective January 1, 2024.
Potentially affected actors named in the source documents. Mention is not a position.
Qualified individuals with rare pediatric diseases
They gain access to out-of-network coverage for routine clinical trial costs at in-network cost-sharing rates.
Group health plans and health insurance issuers
They are required to provide out-of-network coverage for specific clinical trial services and adjust reimbursement structures.
Medicare beneficiaries
They gain coverage for consultation and referral services when participating in category A clinical trials.
Current stage: IN_COMMITTEE.
Floor Vote.
Summary
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Why It Matters
If passed, this bill would ensure that families of children with rare diseases do not face higher out-of-pocket costs when seeking specialized care at out-of-network facilities for approved clinical trials, effective January 1, 2024.
Frequently Asked Questions
Does this bill apply to my private health insurance?
What costs are covered for out-of-network clinical trials?
News Coverage
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Expansion of Clinical Trial Coverage
The bill shifts the burden of out-of-network costs for rare pediatric disease trials from the patient to the insurance provider, aligning with broader efforts to increase clinical trial participation.
Analysis Score
0–100- Significance75How much this matters to a regular citizen
- Controversy20Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz30Current news / social attention level
Publisher tools